

Applicant: Ilya Trakht  
Serial No.: 09/767,578  
Filed: January 23, 2001  
Page 3

In the Claims:

Please cancel non-elected claims 1, 2, 8, 13-28, 35-39, 47, 60 and 61 without disclaimer or prejudice to applicant's right to pursue the subject matter of these claims at a later date in a continuing application.

In accordance with 37 C.F.R. §1.121(c), please amend claims 29 and 30 as indicated below. A marked-up version of the amended claims is attached hereto as Exhibit D.

29. (Amended) A method of producing a monoclonal antibody comprising:

- (a) forming a tetroma cell by fusing a lymphoid cell capable of producing antibody with a trioma cell which does not produce any antibody, wherein the trioma cell is obtained by fusing a heteromyeloma cell which does not produce any antibody with a human lymphoid cell; and
- (b) incubating the tetroma cell formed in step (a) under conditions permissive to the production of antibody by the tetroma cell, thereby producing the monoclonal antibody.

30. (Amended) A method of producing a monoclonal antibody specific for an antigen associated with a condition in a subject comprising:

- (a) forming a tetroma cell by fusing a lymphoid cell capable of producing antibody with a trioma cell which does not produce any antibody, wherein the trioma cell is obtained by fusing a heteromyeloma cell which does

Applicant: Ilya Trakht  
Serial No.: 09/767,578  
Filed: January 23, 2001  
Page 4

- not produce any antibody with a human lymphoid cell;
- (b) incubating the tetroma cell formed in step (a) under conditions permissive to the production of antibody by the tetroma cell;
- (c) selecting a tetroma cell producing a monoclonal antibody;
- (d) separately contacting the monoclonal antibody of step (c) with (1) a sample from a subject with the condition, and (2) a sample from a subject without the condition, under conditions permissive to the formation of a complex between the monoclonal antibody and the sample, wherein the sample from the subject with the condition contains the antigen;
- (e) detecting the complex formed between the monoclonal antibody and the sample;
- (f) determining the amount of complex formed in step (e); and
- (g) comparing the amount of complex determined in step (f) for the sample from the subject with the condition with amount determined in step (f) for the sample from the subject without the condition, a greater amount of complex formation for the sample from the subject with the condition indicating that a monoclonal antibody specific for the antigen specific for the condition is produced.
- b3  
Confidential*

REMARKS

Claims 1, 2, 8, 13-39, 47, 60 and 61 are pending in the subject application. Applicant has hereinabove canceled non-elected claims 1, 2, 8, 13-28, 35-39, 47, 60 and 61 without disclaimer or